Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Investments: 2010-2023

Historic Long-Term Investments for Gyre Therapeutics (GYRE) over the last 8 years, with Dec 2023 value amounting to $49.7 million.

  • Gyre Therapeutics' Long-Term Investments rose 22.34% to $49.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $49.7 million, marking a year-over-year increase of 22.34%. This contributed to the annual value of $49.7 million for FY2023, which is 22.34% up from last year.
  • As of FY2023, Gyre Therapeutics' Long-Term Investments stood at $49.7 million, which was up 22.34% from $40.6 million recorded in FY2022.
  • Gyre Therapeutics' 5-year Long-Term Investments high stood at $49.7 million for FY2023, and its period low was $2.5 million during FY2020.
  • Moreover, its 2-year median value for Long-Term Investments was $45.2 million (2022), whereas its average is $45.2 million.
  • Data for Gyre Therapeutics' Long-Term Investments shows a peak YoY increased of 22.34% (in 2023) over the last 5 years.
  • Over the past 3 years, Gyre Therapeutics' Long-Term Investments (Yearly) stood at $2.5 million in 2020, then reached $40.6 million in 2022, then grew by 22.34% to $49.7 million in 2023.